UVM oncologist Kara Landry, M.D., assistant professor of medicine at the Larner College of Medicine, spoke with NBC5 about the UVM Cancer Center’s participation in a nationwide OFSET clinical trial exploring whether chemotherapy and radiation are effective treatments for early-stage breast cancer. The OFSET trial is a Phase III clinical study aimed at evaluating the effectiveness of adding chemotherapy to hormonal therapy and ovarian function suppression in premenopausal women with early-stage, hormone-sensitive breast cancer.
“For these patients that are eligible for the OFSET Trial, it’s really unclear how much benefit chemotherapy has,” Dr. Landry said, “so, that’s what this study aims to explore.”